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REVIEW

Evaluation and treatment of infertile women
with Asherman syndrome: an updated review
focusing on the role of hysteroscopy
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KEY MESSAGE

Asherman syndrome is a rare pathology secondary to intrauterine adhesion formation characterized by
menstrual disorders and reproductive dysfunction. Hysteroscopy is currently considered the gold standard for
its treatment because it allows simultaneous diagnosis and treatment. Asherman syndrome requires further
basic science research to determine its cause and potential preventative measures.
ABSTRACT

Asherman syndrome is a rare acquired clinical condition resulting in the obliteration of the uterine cavity causedby
the presence of partial or complete fibrous intrauterine adhesions involving at least two-thirds of the uterine cavity
potentially obstructing the internal cervical orifice. Common reported symptoms of the disease are alterations of
the menstrual pattern with decreased menstrual bleeding leading up to amenorrhoea and infertility. Hysteroscopy is
currently considered the gold standard diagnostic and therapeutic approach for patients with intrauterine adhesions.
An integrated approach, including preoperative, intraoperative and postoperative therapeutic measures, however,
are warranted owing to the complexity of the syndrome. This review aims to summarize the most recent evidence
on the recommended preoperative, intraoperative and postoperative procedures to restore the uterine cavity
and a functional endometrium, as well as on the concomitant use of adjuvant therapies to achieve optimal fertility
outcomes.
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INTRODUCTION

A

sherman syndrome is
an acquired condition
characterized by the
development of obliteration
of the uterine cavity caused by partial
or complete fusion of opposing uterine
walls by fibrous adhesions, also referred
to as synechiae, leading to menstrual
disorders such as amenorrhoea or
decreased menstrual flow, severe
cramping pain, subfertility and adverse
pregnancy outcomes, or all (Yu et al.,
2008). Although intrauterine adhesions
were first described by Fritsch (1894),
Joseph Asherman described the
pathophysiology, clinical significance and
the potential utilization of hysteroscopy
for the treatment of intrauterine
adhesions in 1950 and thus it is referred
to as Asherman syndrome (Asherman,
1950).
It is important to clarify that Asherman
first described in 1948 a specific type
of secondary amenorrhoea after
complicated labour or abortion caused
by a stenosis or blockage of the cervical
internal orifice. Asherman stated
that this ‘amenorrhoea traumatica’ is
not functional but organic; ovulation
continues to occur but the uterus does
not react and the endometrium remains
in a state of inactivity. Hormonal therapy
is neither reasonable nor effective,
whereas simple removal of the blockage
is sufficient to restore menstruation to
normal (Asherman, 1948). Therefore,
the resulting secondary amenorrhoea
is a form of endometrial deactivation
in the presence of cervical stenosis
with a normal uterine cavity and is
not Asherman syndrome caused by
intrauterine adhesions (IUA).
Although the cause of IUA is thought to
be associated with vigorous curettage
or uterine surgery involving the uterine
cavity, pelvic infections such as pelvic
inflammatory disease as a result of
sexually transmitted infections may also
lead to Asherman syndrome. Other
causes of intrauterine infections, such as
tuberculosis or schistosomiasis leading
to IUA, are particularly important in
developing countries.
Establishing prognostic criteria of this
syndrome is challenging as it depends on
multiple pathophysiologic factors as well
as the need to use adequate diagnostic
tools to determine the extent of the

disease to then establish the appropriate
therapy. Once the extent of the condition
is determined, the next challenge is
to plan the appropriate treatment to
restore the intrauterine anatomy and
potentially the physiology of the uterine
cavity and also to prevent recurrence
of IUA to enhance and restore normal
reproductive function.
Preoperative assessment of Asherman
syndrome includes the use of transvaginal
ultrasonography, hysterosalpingography
(HSG), saline infusion sonohysterography
and, in particular, hysteroscopy (Schlaff
and Hurst, 1995; Salle et al., 1999;
Reyes-Munoz et al., 2019). The use
of a combination of preoperative,
intraoperative and postoperative
measures, as well as adjuvant therapy to
prevent recurrence of IUA, is generally
accepted as the best approach to reduce
clinical symptoms, enhance fertility and
obtain good reproductive outcomes.
Such procedures include ultrasounddirected hysteroscopic adhesiolysis,
mechanical lysis of adhesions to separate
the fused uterine walls and the use of
adjuvant therapy with systemic oestrogen
with or without progestin administration
in conjunction with intrauterine barriers
and adhesion preventing agents to
induce endometrial proliferation (Farhi
et al., 1993; Zikopoulos et al., 2004). This
integrated approach improves prognosis
and prepares the uterine cavity for
conception, especially when interventions
aimed at promoting endometrial healing
are used.
The aim of this review is to present
the most recent evidence on
the recommended preoperative,
intraoperative and postoperative
procedures to restore the anatomy
of the uterine cavity and a functional
endometrium, as well as to summarize
use of adjuvant therapies to achieve
optimal fertility outcomes.

MATERIALS AND METHODS
MEDLINE, Embase, Web of Sciences,
Scopus, ClinicalTrial.gov, OVID
and Cochrane Library were used to
searched for all the articles related to
Asherman syndrome from the inception
of the database up to October 2019. A
combination of the following text words
were used to identify relevant studies:
hysteroscopy, intrauterine synechiae,
Asherman syndrome, infertility. The
selection criteria of this narrative review

included randomized clinical trials,
non-randomized controlled studies
(observational prospective, retrospective
cohort studies, case-control studies, case
series) and review articles of Asherman
syndrome in infertile women and the
diagnostic and therapeutic role of
hysteroscopy. A review of articles also
included the abstracts of all references
retrieved from the search. Articles not
written in English, conference papers
and reviews, and studies with information
overlapping another publication, were
excluded. In the event of overlapping
studies, the most recent, comprehensive
study, or both were selected.
Preoperative assessment
Advances in endoscopic technology
allow the direct exploration of the
uterine cavity and, consequently,
more accurate diagnosis and greater
management options for intrauterine
pathology. Asherman syndrome should
be suspected in patients presenting with
menstrual changes, such as decreased
menstrual flow, amenorrhoea or
dysmenorrhoea in association with a
history of infertility, especially in patients
with previous curettage or intrauterine
surgery. The diagnosis is commonly
obtained by imaging the uterine cavity
with contrast (hysterosalpingogram).
Hysteroscopy, however, is considered
the gold standard technique for the
evaluation of the uterine cavity for
the diagnosis of Asherman syndrome
(Wamsteker, 1995; Vitale et al., 2017;
De Franciscis et al., 2019). It allows
direct access and a real-time view of the
endometrial cavity, accurately confirming
the presence, extent and morphological
characteristics of intrauterine adhesions
and the quality of the endometrium.
In addition, it enables an accurate
description of the location, the degree of
the adhesions and classification allowing
treatment at the same time ‘see and
treat’ (Reyes-Munoz et al., 2019).
Hysterosalpingography is a cost-effective
diagnostic method used to assess tubal
patency in addition to the size, shape and
contents of the uterine cavity. Before the
widespread use of hysteroscopy, HSG
was the preferred diagnostic modality
for Asherman syndrome showing
contrast filling defects described as
homogeneous opacity surrounded by
sharp edges (Magos, 2002). Severe
Asherman’s syndrome is characterized
by a completely distorted and narrow
uterine cavity occluding the uterine ostia.
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Hysterosalpingography has a diagnostic
sensitivity of 75–81%, a specificity of
80% for the diagnosis of IUA but is a
diagnostic tool with a high false-positive
rate (positive predictive value 50%) (Yu
et al., 2008).
Transvaginal ultrasound is frequently
included in the initial evaluation of
women with gynaecologic complaints.
Intrauterine adhesions are characterized
by an echo-dense pattern resulting in
difficult identification of the endometrial
lining, which contains one or more
translucent ‘cyst-like’ areas (Yu et al.,
2008). Although ultrasound has been
reported to have low diagnostic accuracy
(Farhi et al., 1993; Salle et al. 1999;
Soares et al., 2000; Magos, 2002;
Zikopoulos et al., 2004), it allows an
adequate mapping of the uterine cavity
when complete obstruction of the cervix
precludes an HSG or hysteroscopy to
be carried out. The ultrasound scan
can also be useful during hysteroscopic
adhesiolysis to guide the procedure and
prevent uterine perforation. Compared
with laparoscopic-guided adhesiolysis,
ultrasound-guided adhesiolysis is
certainly less invasive and has a lower
cost, avoiding potential laparoscopic
complications with a similar rate of
uterine perforation risk (Schlaff and
Hurst, 1995). Moreover, published
research supports ultrasound as a
better predictor of the surgical repair,
because it allows the assessment of
residual endometrium: if the residual
endometrium after the initial treatment
is thin or no endometrium is seen
during the transvaginal ultrasound, the
obstetric outcomes are greatly decreased
(Kresowik et al. 2012).
The role of contrast, i.e saline
and gel, infusion sonography or
sonohysterography has also been widely
investigated. It has a diagnostic sensitivity
of 75% and a positive predictive value
of 43%, similar to that reported for
HSG. Salle et al. (1999) reported the
same sensitivity and specificity when
SHG was compared with standard HSG.
Recently, a retrospective study involving
149 women with intrauterine anomalies
demonstrated a significant difference
in general accuracy at diagnosing
intrauterine pathology favouring SHG
(50.3% in the HSG group and 81.8% in
the SHG group) (Acholonu et al., 2011).
To the best of our knowledge, current
data about the role of three-dimensional

ultrasound imaging (3D-US) in the
diagnosis of intrauterine adhesions are
limited (Knopman and Copperman,
2007). However, 3D-US is taking on
a growing role in the evaluation of
intrauterine synechiae, with a sensitivity
of 87% and a specificity of 45%, which
is higher than those obtained with
transvaginal ultrasound and SHG.
Moreover, 3D-US and intrauterine saline
infusion, known as three-dimensional
sonohysterography both in combination
with or without three-dimensional power
Doppler have recently been proposed
as a possible imaging modality for the
diagnosis of intrauterine pathology. Only
low-quality data, however, are reported
to date on the efficacy of this technique
in the diagnosis of intrauterine synechiae
(Abou-Salem et al., 2010) and, until more
robust evidence becomes available, the
high cost of three-dimensional ultrasound
precludes its use in daily clinical practice.
Magnetic resonance imaging represents
a supplementary diagnostic tool,
especially in the case of complete
obliteration of the cervical canal.
Intrauterine adhesions are depicted as
low signal intensity on T2-weighed image
inside the uterus (Bacelar et al., 1995).
Magnetic resonance imaging is generally
not necessary and is not used routinely
for the diagnosis of Asherman syndrome
as it is not considered to be costeffective as a routine diagnostic tool.
Despite the availability of the multiple
imaging techniques discussed above,
hysteroscopy remains the gold standard
for the diagnosis and management
(assessment and treatment) of
Asherman’s syndrome.
Intraoperative assessment
Lysis of IUA is considered the gold
standard treatment of patients diagnosed
with Asherman syndrome; nevertheless,
no randomized controlled trials have
compared outcomes of surgical
intervention with expectant management
or between different methods of surgical
intervention. Any surgical intervention
aims to restore as much as possible
the anatomy of the endometrial cavity
and the cervical canal, restoring the
normal volume and shape to facilitate
the communication between the
uterine cavity, the cervical canal and the
fallopian tubes, subsequently allowing
normal menstrual flow and adequate
sperm transportation for fertilization and
implantation.
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To date, hysteroscopic adhesiolysis,
using a variety of instruments with
or without energy, has emerged as
the gold standard technique for the
treatment of intrauterine adhesions
allowing the ‘see and treat’ approach.
Hysteroscopy, reveals important features
of intrauterine synechiae, such as their
number, location, extension, structure
and consistency. The location of the
adhesions can be central or marginal
and their extension can be described as
mild, moderate or severe: in the latter
case, only fibrous tissue is seen with small
irregular endometrial bridges (Worldwide,
2010; Nappi and Di Spiezio Sardo, 2014).
The structure and consistency of the
adhesions depend on the predominant
component that is present, i.e. mucosal,
muscular or fibrous.
March et al. (1978) introduced a
classification based on the extension
(mild, moderate and severe) of
intrauterine synechiae. The American
Fertility Society (1988) developed a new
scoring system for classification of IUA
taking into account menstrual history and
hysteroscopic and hysterosalpingographic
findings: a prognostic classification in
three stages (stage I: mild; stage II:
moderate; stage III: severe) resulted.
The European Society of Hysteroscopy
reported a more detailed classification of
Asherman syndrome based on the nature
and consistency of the adhesions but
this classification is more cumbersome
to use in clinical practice than the
former (Wamsteker and De Blok,
1995). The most recent classification
takes into account the characteristics
of intrauterine synechiae as well as the
gynaecologic and obstetric history of
the patients: patients have an excellent
prognosis if a numerical score ranges
from 0 to 4 (level 1, mild), whereas the
prognosis is considered favourable if
the score ranges from 5 to 10 (level 2,
moderate) or poor if scoring from 11 to
22 (level 3, severe). This classification,
however, has been validated only on a
small number of patients and requires
further studies before it is incorporated
in clinical practice (Nasr et al. 2000)
(TABLE 1).
In the case of mild filmy adhesions, office
hysteroscopy without general anaesthesia
can be safely carried out to allow the
restoration of a normal uterine cavity by
breaking the adhesions using only the
uterine distension pressure and the tip
of the hysteroscope (Sugimoto, 1978).
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TABLE 1 THREE MAIN CLASSIFICATION SYSTEMS OF INTRAUTERINE
ADHESIONS
Authors (year of publication) Classification
March et al. (1978)

IUA classified as mild, moderate or severe based on hysteroscopic
assessment of their extension.

American Fertility Society (1988)

Classification system including the extent of uterine cavity involved
(<1/3, 1/3–2/3, >2/3) and the type of IUA (filmy, filmy-dense, dense)
as well as the menstrual pattern (normal, hypomenorrhoea and
amenorrhoea)
Stage I: mild (score 1–4)
Stage II: moderate (score 5–8)
Stage III: severe (score 9–12)

European Society for Hysteroscopy Six types (I–VI) of IUA classified as following:
(Wamsteker and De Blok, 1995)
Type I: subtle or velamentous IUA
Type II: single fibrous synechiae
Type IIa: obliterating isthmic synechiae in presence of normal
uterine cavity
Tipe III: multiple fibrous synechiae with frequent obliteration of one
of the tubal ostium
Type IIIa: wide involvement of uterine walls
Type IIIb: combination of types III and IIIb
Type IV: fusion of the uterine cavity owing to extensive fibrous synechiae, with frequent obliteration of both tubal ostium
Nasr et al. (2000)

Classification system including the characteristics of IUA as well
as the gynaecologic and obstetric history of the patient (isthmic
synechia, viscous synechia, dense synechia, tubal ostia, menstrual
pattern and reproductive anamnesis).
Excellent prognosis: total score 0–4 (grade 1, mild)
Favourable prognosis: total score 5–10 (grade 2, moderate)
Severe prognosis: total score 11–20 (grade 3, severe)

IUA, intrauterine adhesions.

More vigorous approaches are required,
however, for severe and dense adhesions,
especially if they completely occlude the
uterine cavity or if they do not allow the
insertion of the hysteroscopic sheath
inside the cervix. Intuitively, adhesiolysis
should be started at the lowest part of
the uterine cavity and advanced upwards
as the uterine cavity is being restored (Yu
et al., 2008).
The adhesions situated in the central part
of the uterine cavity, if filmy and easy to
break, should be separated first which
will allow adequate distension of the
uterine cavity. Finally, if more dense or
lateral adhesions are present, they should
be treated at the end of the procedure
to minimize the risk of bleeding, uterine
perforation, or both (Deans and Abbott,
2010).
It has been reported that even the use
of a sharp needle (Touhy needle) for
hysteroscopic adhesiolysis has a good rate
of success in normalizing the menstrual
cycle. Data on further fertility after the

procedure are not consistent (Broome
and Vancaillie, 1999). Cold-scissors were
used to break the adhesions, and this is
thought to be a superior method because
it does not cause thermal damage to
the residual endometrium. On the
other hand, the use of ‘hot’ instruments
(using energy, electric or laser) may
be associated with potential thermal
damage to the residual endometrial
tissue promoting scar formation (Al-Inany,
2001; Yu et al., 2008). In any case, in the
presence of extensive or dense adhesions,
the treatment should be carried out
by an expert hysteroscopist using the
instruments that they are most familiar
with.
Prevention of adhesion recurrence
After hysteroscopic adhesiolysis,
intrauterine devices (IUD), stents, or
balloon catheters are frequently used
to reduce the rate of postoperative
adhesion formation, although data on
their effect on preventing recurrence of
IUA and subsequent fertility outcomes
when these barriers are used are limited

(Aagl Elevating Gynecologic Surgery,
2017).
Intrauterine devices and intrauterine
adhesions
After hysteroscopic adhesiolysis, the
recurrence rate of IUA has been
reported to range from 3.1% to 23.5%
(Valle and Sciarra, 1988; Pabuccu et al.,
1997). Recurrent adhesions are usually
thin and filmy (Shokeir et al., 2008).
Intrauterine devices have been used to
prevent adhesion recurrence because
of their mechanical effect of separating
the anterior and posterior uterine walls
(Conforti et al., 2013), which may help
physiological endometrial regeneration.
Although many investigators have
reported good results (Polishuk and
Weinstein, 1976; Ventolini et al., 2004),
data on the preferred size and the type
of IUD to prevent IUA recurrence are still
lacking. Moreover, IUD may induce the
release of inflammatory agents that may
aggravate endometrial injury delaying
healing and endometrial regeneration
(March, 1995). Although it is reported
that, after the insertion of an IUD a
significant number of women regained
regular menses (Vesce et al., 2000),
the levonorgestrel-releasing IUD should
be avoided because of its suppressing
effect on oestrogen receptors, which
are considered necessary for normal
regeneration of the endometrium (Deans
and Abbott, 2010). It is important to
note that the same rate in adhesion
reformation has been found among
women randomized to receive IUD
device, oestrogens treatment or no
treatment after hysteroscopic septum
resection (Tonguc et al., 2010).
Intrauterine balloons
An intrauterine balloon stent is another
mechanical method frequently used to
prevent the reformation of adhesions
after intrauterine adhesiolysis (March,
2011). It consists of a silicon triangular
shape device fitting the uterine cavity
(Cook Medical Inc, Bloomington, USA).
Intrauterine balloon stent can be inserted
immediately after the procedure with
good results in fertility outcome and
prevention of adhesion recurrence
(March, 2011; Lin et al., 2013). A
prophylactic broad-spectrum antibiotic is
always recommended for the duration of
the stent inside the uterine cavity.
Foley catheters
A standard paediatric Foley catheter
is another commonly used method to
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prevent the recurrence of IUA after
hysteroscopic adhesiolysis (Asherman,
1950March et al., 1978; Ismajovich et al.,
1985). In a study involving 25 women
with moderate and severe adhesions,
a fresh amnion graft draped over a
Foley catheter balloon inserted into the
uterus immediately after hysteroscopic
lysis of intrauterine adhesions and left
inside for 2 weeks showed a significant
reduction of adhesion reformation
(Amer and Abd-El-Maeboud, 2006).
Compared with IUD, Foley catheter
showed a higher conception rate
(33.9% versus 22.5%), reporting also
restoration of normal menstrual pattern
in 81% of women (Orhue et al., 2003).
Although positive outcomes have been
reported, randomized controlled trials
on the efficacy of Foley catheters in the
prevention of IUA, are not available.
Limits of this approach are mainly the
risk of potential uterine perforation,
ascending infection from the vagina and
patient discomfort.
Hyaluronic acid and other antiadhesion barriers
Over the past 10 years, hyaluronic acidderived products have been developed,
showing a possible role in gynaecologic
surgery to prevent intra-abdominal and
intrauterine adhesions (Pellicano et al.,
2003, Guida et al., 2004). Hyaluronic
acid mechanically inhibits adhesions
formation owing to the temporary
formation of a barrier (Reijnen et al.,
2000). Autocross-linked hyaluronic
acid (Hyalobarrier©) is frequently used
after gynaecological abdominal surgery
and consists of a viscous gel formed
by the autocross-linked condensation
of hyaluronic acid, preventing
intraperitoneal adhesions formation
after laparoscopic myomectomy and
intrauterine adhesions after hysteroscopic
procedures (Mais et al., 2012).
Other anti-adhesion barrier products
have been proposed to reduce IUA
recurrences, such as the one made
of chemically modified hyaluronic
acid (sodium hyaluronate) and
carboxymethylcellulose (Seprafilm©) and
a newer hyaluronic acid derived (alginate
carboxymethylcellulose hyaluronic acid).
Scientific evidence is still not sufficiently
consistent to allow the recommendation
of one product over another.
Bone marrow-derived stem cell
The potential to regenerate severely
damaged endometrium with human stem

cell treatment has also been explored
with promising results in animal models
and humans (Alawadhi et al., 2014; Kilic
et al., 2014; Kuramoto et al. 2015). In a
prospective study by Santamaria et al.
(2016), 16 women with IUA confirmed by
hysteroscopy were treated with uterine
intravascular infusions of bone marrowderived stem cell (BMDSC). During the
follow-up period, menstrual function
returned to normal within 6 months after
BMDSC infusion, with three spontaneous
pregnancies and seven pregnancies
after IVF and embryo transfer reported
(Santamaria et al. 2016).
Postoperative management
One out of three women with Asherman
syndrome who had mild to moderate
IUA (Preutthipan and Linasmita, 2003)
and two out of three who had severe
IUA (Yang et al., 2016) had recrrence of
IUA after hysteroscopic adhesiolysis. A
clinical goal after hysteroscopic surgery
is to obtain a restored normal uterine
cavity and a functional endometrial
layer, especially in women desiring
future fertility. According to the
American Association of Gynecologic
Laparoscopists and the European
Society of Gynaecological Endoscopy
guidelines, a repeated hysteroscopy
is recommended for the follow-up
assessment of the uterine cavity after
treatment of IUA (Aagl Elevating
Gynecologic Surgery, 2017).
Conventional wisdom dictates that good
endometrial healing may be achieved in
the presence of high oestrogen levels.
No clear consensus, however, has been
reached on when exogenous hormonal
therapy should be started, or on the
type of regimen, dose and duration
of treatment. The latest evidence on
hormonal therapy aiming to restore the
endometrial thickness is that both lower
dosage (4 mg) and a higher dose (10
mg) of oestradiol valerate given daily in
the postoperative period are effective in
reducing adhesion formation, with better
results associated with the higher dose.
Both doses, however, allowed a normal
restoration of menstrual patterns, but
results for fertility outcomes have not yet
been reported (Liu et al., 2019).
Prolonged preoperative and
postoperative treatment with oestrogens
has been reported in a small study
including 12 patients with severe
Asherman syndrome. All women
resumed a normal menstrual pattern
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and six of them became pregnant
(Myers and Hurst 2012). Oestradiol
valerate 4 mg per day for 4 weeks and
medroxyprogesterone acetate (MPA), 10
mg per day during the last 2 weeks of
treatment have also been recommended
as an ideal treatment after surgery for
Asherman syndrome (Yu et al., 2008).
It has been reported that an oestrogen–
progestin combination administered
after curettage for postpartum
haemorrhage or incomplete miscarriage
increases the endometrial thickness.
Specifically, after 21 days of treatment,
the transvaginal ultrasound showed a
thicker endometrium with larger width
and volume (Farhi et al., 1993). Also,
Tsui et al. (2014) proposed oestrogen
treatment (8–10 weeks) after removal
of the balloon and second look
hysteroscopy. Transvaginal ultrasound
may be used to assess the endometrial
thickness and IVF and embryo transfer
can be performed when the endometrial
thickness exceeds 5 mm (Tsui et al.,
2014).
Finally, after the failure of hormonal
therapy in restoring the endometrium
(Nagori et al., 2011), several studies have
been conducted over the past 10 years
exploring new horizons, including the
use of infusing bone marrow derivates
or stimulating endometrial stromal stem
cells. Data on the effectiveness of stem
cells in regenerating a physiologically
normal endometrial lining and uterine
cavity, however, are still inadequate. In
this context, solid scientific evidence is
still needed.
In conclusion, Asherman syndrome
is a rare pathology secondary to
intrauterine adhesion formation that is
associated with menstrual disorders and
reproductive dysfunction. Hysteroscopy
is currently considered the gold standard
for management because it allows
simultaneous diagnosis and treatment
(‘see and treat’). Although significant
advances have been made in the
restoration of the endometrial cavity over
the past decade, complete restoration
of a normal functional endometrial lining
has not been achieved. Preliminary
evidence suggests a promising role
of BMDSC in enhancing endometrial
healing and reproduction. The evidence
on the role of BMDSC in clinical
practice, however, is still limited and this
treatment should not be offered outside
of rigorous research protocols.
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Finally, a consensus-based adjuvant
therapy, including the use of intrauterine
stents and exogenous hormonal therapy
aimed to achieve adequate endometrial
growth and to prevent recurrence of
IUA, has not yet been established.
Restoration of a functional endometrial
lining is one of the most important
challenges for successful reproductive
outcomes. Although rare but with great
clinical significance, Asherman syndrome
requires further basic science research
work to determine its caue and potential
preventing measures. Well-designed
clinical trials are needed to determine
the most appropriate diagnostic and
therapeutic modalities.
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